Xiaodong Tang, M.D.

Chief
Peking University People's Hospital, China (People's Republic)

Current Positions
Director of Orthopedic oncology department, Peking University People’s Hospital
Professor of Peking University Health Science Center
Specialities
Bone & Soft Tissue Tumour Medicine
Spine tumour
Educational and Training Background
1992-1997 B.M. - Beijing Medical Universtiy,.
2000-2003 M.D. - Peking University Health Science Center
2005-2006 Tumour Fellow - Orthopedic Service, Royal Adelaide Hospital, South Australia
Professional Affiliations
2003 - present Member: Chinese Orthopaedic Association
2010 - present Member: Chinese Anti-Cancer Asssociation
2016 – present Board Member: Asia-Pacific Musculoskeletal Tumour Society
2021 – present Board Member: SICOT China Chapter

Poster(s):

• (P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA

• (P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS

• (P 58) CHEMOTHERAPY-INDUCED EVOLUTION OF OSTEOSARCOMA REVEALED BY SINGLE-CELL RNA SEQUENCING

• (P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP

• (P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL

• (P 464) INDOCYANINE GREEN FLUORESCENCE IMAGING MAY DETECT TUMOUR RESIDUALS DURING SURGERY FOR BONE AND SOFT-TISSUE TUMOURS

• (P 487) EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES